Trials / Completed
CompletedNCT02336555
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
A Randomized Clinical Trial to Study the Efficacy, Safety, and Tolerability of MK-8291 in Subjects With Post-Herpetic Neuralgia With Allodynia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia. The primary hypothesis is that when compared to placebo, treatment with MK-8291 reduces the change from Baseline in participant-reported pain intensity by 1 on an 11-point numeric rating scale.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8291 | MK-8291 oral tablets |
| DRUG | Placebo | Placebo oral tablets |
Timeline
- Start date
- 2015-03-12
- Primary completion
- 2016-02-29
- Completion
- 2016-02-29
- First posted
- 2015-01-13
- Last updated
- 2019-12-09
- Results posted
- 2019-12-09
Source: ClinicalTrials.gov record NCT02336555. Inclusion in this directory is not an endorsement.